T. Cerny

Discipline

Psychologie (1)

Type de document

Articles (7)

Co-auteur

Date

Source

Mot-clé

Human beings (7) toxicité (6) Treatment (6) Patients (6) Toxicology (6) Patients (6) thérapie (5) dose (5) adulte (5) taux (5) Therapeutics (5) Cycles (5) Older people (5) adulte (5) procès (4) survie (4) Dose-response relationship (4) Chemotherapy (4) Methods (4) Tumors (4) Thrombocytopenia (4) Survival (4) Days (4) Chemotherapy (4) Doxorubicin (4) Methods (4) administration (3) temps (durée) (3) dosage (3) Neutropenia (3)

Documents écrit par T. Cerny (7) | parle de T. Cerny (0)

Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro.
V. Cagno et al. (12 juil. 2021)
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
S. Leyvraz et al. (20 nov. 2006)
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
S. Leyvraz et al. (2006)
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
D.C. Betticher et al. (2006)
Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK).
T. Cerny et al. (1999)
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK)
S. Leyvraz et al.
Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial.
R. Stupp et al. (1998)